The role of protein kinase C isoenzymes in the growth inhibition caused by bryostatin 1 in human A549 lung and MCF‐7 breast carcinoma cells
The DOI matches its Crossref record.
Abstract
Bryostatin I is a natural product currently under clinical evaluation as an antitumor agent. Like the tumor‐promoting phorbol ester 12‐O‐tetradecanoylphorbol‐13 ‐acetate (TPA) it activates protein kinase C (PKC). Bryostatin I inhibits the growth of the human‐derived A549 lung and MCF‐7 adenocarci‐noma cell lines, but much more weakly than TPA. The hypotheses were tested that differences between cell lines in their response to bryostatin I are related to cellular PKC isotype content, and that differences between TPA and bryostatin I in their effects on cell growth are associated with differential abilities to modulate specific PKC isoenzymes. PKC isozyme profiles were studied by Western‐blot analysis in the cytosol, particulate and nuclear fractions of A549 and MCF‐7 cells. PKCs‐α, −ϵ and −ζ were detected in both cell types with predominant location in the cytosol. Separation of cytosolic PKC isoenzymes in A549 cells by hydroxylapatite column chromatography and determination of PKC activity in fractions yielded a major peak which contained PKC‐α. Exposure of cells to bryostatin I or TPA for 30 min caused the redistribution of PKCs‐α and −ϵ from the cytosol to the particulate and nuclear fractions in a concentration‐dependent fashion. PKC −ϵ was completely down‐regulated by exposure to 10 nM bryostatin I for 18 hr or to TPA for 24 hr. Down‐regulation of PKC‐α was partial at 10 nM and complete at I μM of either agent. Bryostatin I inhibited incorporation of [3 H]‐labelled thymidine into cells only transiently, whereas TPA arrested growth for several days in A549 cells and irreversibly in MCF‐7 cells. A549 cells, in which PKC was depleted by exposure to phorbol ester for 9 weeks, were resistant towards bryostatin‐induced inhibition of DNA synthesis. The results suggest that the susceptibility of adenocarcinpma cells towards bryostatin‐induced growth delay are determined by cellular levels of PKCs‐α and/or −ϵ. However, differences between bryostatin I and TPA in their abilities to inhibit cell growth do not seem to be intrinsically related to differences in redistribution or down‐regulation of specific PKC isoenzymes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Review of survival analyses published in cancer journals
Altman, D., De Stavola, B., Love, S., & Stepniewska, K. (1995) · British Journal of Cancer · doi:10.1038/bjc.1995.364 · Cited by 438
Targeting the protein kinase C family: are we there yet?
Mackay, H. J., & Twelves, C. J. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2168 · Cited by 373
Bryostatin-1: A novel PKC inhibitor in clinical development
Kortmansky, J., & Schwartz, G. K. (2003) · Cancer Investigation · doi:10.1081/cnv-120025095 · Cited by 183
“Bryostatin-1 has been effective as a single agent in vitro and in vivo against several murine tumor cell lines, including melanoma,([54]) sarcoma,([55]) lung,([56]) breast,([56]) and others.”
BackgroundProtein Kinase C as a Therapeutic Target in Non-Small Cell Lung Cancer
Sadeghi, M. M., Salama, M. F., & Hannun, Y. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115527 · Cited by 31
Metadata
- Authors
- Tanwell, C. S., Gescher, A., Bradshaw, T. D., & Pettit, G. R.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 1994-02-15
- Volume
- 56
- Issue
- 4
- Pages
- 585-592
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W2036512276
- Cited by
- 62
- References
- 0
- FWCI
- 2.57
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The role of protein kinase C isoenzymes in the growth inhibition caused by bryostatin 1 in human A549 lung and MCF‐7 breast carcinoma cells. https://app.cochat.ai/papers/10.1002/ijc.2910560420
- The paper
- Tanwell, C. S., Gescher, A., Bradshaw, T. D., & Pettit, G. R. (1994). The role of protein kinase C isoenzymes in the growth inhibition caused by bryostatin 1 in human A549 lung and MCF‐7 breast carcinoma cells. International Journal of Cancer. https://doi.org/10.1002/ijc.2910560420
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.